Targeting insulin-like growth factor in breast cancer therapeutics

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 8-17

  Karamouzis, Michalis V ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; IGF receptor; Insulin like growth factor (IGF); Monoclonal antibody; Signal transduction; Tyrosine kinase

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; BMS 754807; CAPECITABINE; CIXUTUMUMAB; CP 751 871; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXEMESTANE; FIGITUMUMAB; FULVESTRANT; GANITUMAB; LAPATINIB; LETROZOLE; LINSITINIB; MEDI 573; MONOCLONAL ANTIBODY; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASTHENIA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RESISTANCE; CHILL; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; INFUSION RELATED REACTION; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; PRURITUS; PSORIASIS; RECEPTOR DOWN REGULATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR REGRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 84866486496     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.010     Document Type: Review

References (95)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Jemal A., Siegel R., Ward E., Forman D. Cancer Stat CA Cancer J Clin 2011, 61:69-90.
3. Berrino F., De A.R., Sant M., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
4. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
5. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
6. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
7. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
8. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
9. Emde A, Kostler WJ, Yarden Y, on behalf of AROME. Therapeutic strategies and mechanisms of tumorigenesis of HER-2 overexpressing breast cancer. Crit Rev Oncol Hematol;, in press. doi:10.1016/j.critrevonc.2010.09.002.
10. Vera-Ramirez L., Sanchez-Rovira P., Ramirez-Trtosa M.C., et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Heamtol 2011, 80:347-368.
11. Sogno I., Vene R., Ferrari N., et al. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol 2010, 75:2-14.
12. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
13. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
14. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
15. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
16. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824-854.
17. MacDonald R.G., Pfeffer S.R., Coussens L., et al. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science 1988, 239:1134-1137.
18. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009, 30:586-623.
19. Frasca F., Pandini G., Vigneri R., Goldfine I.D. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 2003, 17:73-89.
20. Tian J, Lambertz I, Berton TR, et al. Trnsgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. Mol Carcinog; in press.
21. Potter A.S., Casa A.J., Lee A.V. Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J Cell Biochem 2012, 113:110-121.
22. Scott J., Cowell J., Robertson M.E., et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985, 317:260-262.
23. Sarfstein R., Pasmanik-Chor M., Yeheskel A., et al. The insulin-like growth factor-I receptor (IGF-IR) translocates to the nucleus and autoregulates IGF-1R gene expression in breast cancer cells. J Biol Chem 2012, 287:2766-2776.
24. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007, 6:1-12.
25. Nielsen T.O., Andrews H.N., Cheang M., et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004, 64:286-291.
26. Sciacca L., Costantino A., Pandini G., et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18:2471-2479.
27. Sachdev D., Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006, 11:27-39.
28. Sell C., Rubini M., Rubin R., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993, 90:11217-11221.
29. Dunn S.E., Ehrlich M., Sharp N.J., et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58:3353-3361.
30. Sachdev D., Hartell J.S., Lee A.V., Zhang X., Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004, 279:5017-5024.
31. Zhu C., Qi X., Chen Y., Sun B., Dai Y., Gu Y. P.I3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 2011, 137:1587-1594.
32. Taunk N.K., Goyal S., Moran M.S., Yang Q., Parikh R., Haffty B.G. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010, 96:204-208.
33. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
34. Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010, 11:530-542.
35. Law J.H., Habibi G., Hu K., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246.
36. Shimizu C., Hasegawa T., Tani Y., et al. Expression of insulin-like growth factor 1 in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004, 35:1537-1542.
37. Prat A., Ellis M.J., Perou C.M. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012, 9:48-57.
38. Yerushalmi R., Gelmon K.A., Leung S., et al. Insulin-like growth factor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012, 132:131-142.
39. Fu P., Ibusuki M., Yamamoto Y., et al. Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Treat Rev 2011, 130:307-312.
40. Davison Z., de Blacquiere G.E., Westley B.R., May F.E.B. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011, 13:504-515.
41. Winder T., Giamas G., Zhang W., et al. Use of insulin-like growth factor (IGF) pathway polymorphism IGFIR_rs2016347 to predict tumor recurrence in estrogen receptor-positive breast cancer patients. J Clin Oncol 2011, 29:538.
42. Chatzistamou I., Schally A.V., Varga J.L., et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 2001, 12:761-768.
43. Weckbecker G., Tolcsvai L., Stolz B., Pollak M., Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res 1994, 54:6334-6337.
44. Pritchard K.I., Shepherd L.E., Chapman J.A.W., et al. Randomized trial of tamoxifen versus combined tamoxifen and octeotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 2011, 29:3869-3876.
45. Zhang X., Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 2002, 62:4369-4375.
46. Feng Y., Zhu Z., Xiao X., Choudhry V., Barrett J.C., Dimitrov D.S. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006, 5:114-120.
47. Samani A.A., Chevet E., Fallavollita L., Galipeau J., Brodt P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004, 64:3380-3385.
48. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994, 54:4848-4850.
49. Resnicoff M., Sell C., Rubini M., et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994, 54:2218-2222.
50. Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003, 63:8912-8921.
51. Higano C.S., Yu E.Y., Whiting S.H., et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007, 25:3505.
52. Haluska P., Reinholz M.M., Dueck A.C., et al. Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. J Clin Oncol 2010, 28:TPS129.
53. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, pharmacokinetic and pharmacodynamic study of AMG479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.
54. Kaufman P.A., Ferrero J.M., Bourgeois H., et al. A randomized double-blind, placebo-controlled, phase 2 study of AMG479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). San Antonio breast cancer symposium, CTRC-AACR 2010.
55. Haluska P., Shaw H.M., Batzel G.N., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007, 13:5834-5840.
56. Jassem J., Langer C., Karp D.D., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:7500.
57. Offor O., Sullivan C., Rodov S., et al. Insulin-like growth factor receptor I (IGF1R) inhibitors may be synergistic with chemotherapy in basal breast cancer. San Antonio breast cancer symposium, CTRC-AACR 2010.
58. Scartozzi M., Bianconi M., Maccaroni E., Giampieri R., Berardi R., Cscinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010, 12:361-371.
59. Atzori F., Tabernero J., Cervantes A., et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008, 26:3519.
60. Gao J., Chesebrough J.W., Cartlidge S.A., et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011, 71:1029-1040.
61. Chakravarti B., Siddiqui J.A., Dwivedi S.K.D., et al. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative. Mol Cell Endocrinol 2011, 338:68-78.
62. Hou X., Huang F., Macedo L.F., et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 2011, 71:7597-7607.
63. Wittman M.D., Carboni J.M., Yang Z., et al. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,2] triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem 2009, 52:7360-7363.
64. Haluska P., Dhar A., Hou X., et al. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. J Clin Oncol 2011, 29:TPS111.
65. Litzenburger B.C., Creighton C.J., Tsimelzon A., et al. High IGF-1R activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-1R therapy. Clin Cancer Res 2011, 17:2314-2327.
66. Fox E.M., Miller T.W., Balko J.M., et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011, 71:6773-6784.
67. Gil-Ad I., Shtaif B., Luria D., Karp L., Fridman Y., Weizman A. Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm IGF Res 1999, 9:458-464.
68. Gooch J.L., Van Den Berg C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999, 56:1-10.
69. Guo G., Yan-Sanders Y., Lyn-Cook B.D., et al. Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 2003, 23:2362-2378.
70. Dunn S.E., Hardman R.A., Kari F.W., Barrett J.C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997, 57:2687-2693.
71. Tao Y., Pinzi V., Bourhis J., Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007, 4:591-602.
72. Zhang Y., Moerkens M., Ramaiahgari S., et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011, 13:R52.
73. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824.
74. Knowlden J.M., Gee J.M.W., Barrow D., et al. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2011, 13:R93.
75. Chakraborty A.K., Welsh A., Digiovanna M.P. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010, 120:327-335.
76. Juncker-Jensen A., Lykkesfeldt A.E., Worm J., Ralfkiaer U., Espelund U., Jepsen J.S. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006, 16:224-239.
77. Peretz S., Jensen R., Baserga R., Glazer P.M. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA 2001, 98:1676-1681.
78. Turner B.C., Haffty B.G., Narayanan L., et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997, 57:3079-3083.
79. Wen B., Deutsch E., Marangoni E., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001, 85:2017-2021.
80. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128.
81. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
82. Chakraborty A.K., Liang K., DiGiovanna M.P. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on non-overexpressing breast cancer. Cancer Res 2008, 68:1538-1545.
83. Arteaga C.L., Sliwkowski M.X., Osborne K., Perez E.A., Puglisi F., Gianni L. Treatment of HER-2 positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011, 9:16-32.
84. Reinholz M.M., Dueck A.C., Chen B., et al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 2011, 29:10503.
85. Dokmanovic M., Shen Y., Bonacci T.M., Hirsch D.S., Wu W.J. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance. Mol Cancer Ther 2011, 10:917-928.
86. Becker M.A., Igrahim Y.H., Cui X., Lee A.V., Yee D. The IGF pathway regulates ERa through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011, 25:516-528.
87. Loehberg C.R., Strissel P.L., Dittrich R., et al. Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 2012, 83:480-488.
88. Wang X., Yue P., Chan C.B., et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007, 27:7405-7413.
89. Rodon J., DeSantos V., Ferry R.J., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008, 7:2575-2588.
90. Atzori F., Traina T.A., Ionta M.T., Massidda B. Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol 2009, 4:255-266.
91. Huang F., Greer A., Hurlburt W., et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009, 69:161-170.
92. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010, 107:10791-10798.
93. Fagan D.H., Yee D. Anx IGF1R antibody does not inhibit growth of tamoxifen resistant MCF-7 cells. San Antonio breast cancer symposium, CTRC-AACR 2011.
94. Huang J., Morehouse C., Streicher K., et al. Altered expression of insulin receptor isoforms in breast cancer. PLoS One 2011, 6:e26177.
95. Becker M.A., Hou X., Harrington S.C., et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. San Antonio breast cancer symposium, CTRC-AACR 2011.